Combination of chemotherapy and endocrine treatment in breast cancer - is it still a taboo?

被引:0
|
作者
Wysocki, Piotr J. [1 ]
机构
[1] Jagiellonian Univ, Med Coll, Dept & Clin Oncol, Ul Kopern 50, PL-31501 Krakow, Poland
来源
ONCOLOGY IN CLINICAL PRACTICE | 2024年 / 20卷 / 04期
关键词
chemoendocrine; metronomic; chemotherapy; endocrine treatment; breast cancer; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; TAMOXIFEN; THERAPY; CYCLOPHOSPHAMIDE; PROLIFERATION; MULTICENTER; PALBOCICLIB; FULVESTRANT; METASTASIS;
D O I
10.5603/ocp.100128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
For many years, it has been believed that a combination of endocrine therapies with chemotherapeutic agents should not be used in clinical practice as the treatment for either early or advanced breast cancer. These conclusions resulted from clinical trials conducted several decades ago, which combined a selective estrogen receptor modulator (tamoxifen) with polychemotherapy regimens in early breast cancer patients. However, recent results of clinical trials and cohort studies that evaluated combinations of novel chemotherapy regimens with aromatase inhibitors or fulvestrant demonstrated that chemoendocrine therapy is feasible, safe, and active in patients with HR+ breast cancer at various stages of the disease. This article reviews the available data on the safety, activity, and clinical utility of systemic treatment approaches based on the simultaneous administration of endocrine agents with mainly metronomic chemotherapy.
引用
收藏
页码:302 / 307
页数:6
相关论文
共 50 条
  • [31] Neoadjuvant chemotherapy in combination with surgery in the treatment of local advanced breast cancer
    Zhao, Haixia
    Zhang, Jinying
    Lu, Yanxia
    Jin, Jihai
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (05) : 1402 - 1407
  • [32] Current research status of metronomic chemotherapy in combination treatment of breast cancer
    Liu, Jiaxuan
    He, Maiyue
    Wang, Zijing
    Li, Qiao
    Xu, Binghe
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (11) : 681 - 691
  • [33] A Phase II Study of the Combination of Endocrine Treatment and Bortezomib in Patients with Endocrine Resistant Metastatic Breast Cancer
    Trinh, X. B.
    Van Laere, S. J.
    Deleu, I
    van de Velde, H.
    Van der Auwer, I
    Limame, R.
    Wojtasik, A.
    Maes, H.
    De Mesmaeker, P.
    van Dam, P. A.
    Prove, A.
    Vandebroek, J.
    Rasschaert, M.
    Vermeulen, P. B.
    Dirix, L. Y.
    CANCER RESEARCH, 2009, 69 (24) : 739S - 740S
  • [34] TREATMENT OF INFLAMMATORY BREAST-CANCER WITH COMBINATION CHEMOTHERAPY AND MASTECTOMY VERSUS BREAST CONSERVATION
    BRUN, B
    OTMEZGUINE, Y
    FEUILHADE, F
    JULIEN, M
    LEBOURGEOIS, JP
    CALITCHI, E
    ROUCAYROL, AM
    GANEM, G
    HUART, J
    PIERQUIN, B
    CANCER, 1988, 61 (06) : 1096 - 1103
  • [35] Should endocrine therapy still be used as an initial treatment for postmenopausal women with metastatic breast cancer?
    Orlando, Laura
    Cinieri, Saverio
    FUTURE ONCOLOGY, 2017, 13 (16) : 1361 - 1364
  • [36] Optimal Treatment Duration for Endocrine Sensitive Breast Cancer in the Adjuvant Setting - Still a Matter of Debate
    Jackisch, Christian
    BREAST CARE, 2013, 8 (01) : 86 - 87
  • [37] Early breast cancer in very young women: the interphase between endocrine and chemotherapy treatment
    Francis, P.
    EJC SUPPLEMENTS, 2004, 2 (03): : 66 - 66
  • [38] SEQUENTIAL USE OF ENDOCRINE TREATMENT AND CHEMOTHERAPY IN METASTATIC BREAST-CANCER - EFFECTS ON SURVIVAL
    MANNI, A
    TRUJILLO, J
    PEARSON, OH
    CLINICAL RESEARCH, 1979, 27 (02): : A389 - A389
  • [39] STEROID-RECEPTORS AND RESPONSE TO ENDOCRINE TREATMENT AND CHEMOTHERAPY OF ADVANCED BREAST-CANCER
    VONMAILLOT, K
    GENTSCH, HH
    GUNSELMANN, W
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1980, 98 (03) : 301 - 313
  • [40] A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer
    Trinh, X. B.
    Sas, L.
    Van Laere, S. J.
    Prove, A.
    Deleu, I.
    Rasschaert, M. A.
    Van de Velde, H.
    Vinken, P.
    Vermeulen, P. B.
    van Dam, P. A.
    Wojtasik, A.
    De Mesmaeker, P.
    Tjalma, W. A.
    Dirix, L. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)